Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. (Q53120499)

11 May 2018

title

Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. (English)

1 reference

11 May 2018

main subject

phase II clinical trial

0 references

0 references

1 reference

1 reference

Stephen D. Silberstein

object named as

Stephen Silberstein

1 reference

11 May 2018

Stacey Goode-Sellers

1 reference

11 May 2018

Colleen Twomey

1 reference

11 May 2018

Jane Saiers

1 reference

11 May 2018

John Ascher

1 reference

11 May 2018

language of work or name

English

0 references

publication date

19 November 2012

1 reference

11 May 2018

published in

Cephalalgia

1 reference

11 May 2018

volume

1 reference

11 May 2018

issue

1 reference

11 May 2018

page(s)

101-111

1 reference

11 May 2018

Acute and prophylactic treatments for migraine: present and future

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Anticonvulsants in migraine prophylaxis: a Cochrane review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

EFNS guideline on the drug treatment of migraine - report of an EFNS task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Possible mechanisms of valproate in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Gabapentin for the treatment of cancer-related pain syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Efficacy of gabapentin in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Role of antiepileptic drugs as preventive agents for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Placebo response in the prophylaxis of migraine: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0333102412466968

21 January 2018

Identifiers

DOI

10.1177/0333102412466968

1 reference

11 May 2018

1 reference

11 May 2018